AZ’s blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER says
AstraZeneca’s newly approved, first-in-class hypertension drug Baxfendy does not clear the bar for effectiveness relative to its price,…
Browsing Tag